Miyaji N, Oyama T, Uchiyama N, Kobayashi H, Ito Y, Akazaki I, Shinohara S, Tanohata S
Department of Radiology, Kagoshima University, School of Medicine.
Nihon Igaku Hoshasen Gakkai Zasshi. 1991 Mar 25;51(3):270-81.
Results of 104 cases of non-small cell lung cancer (NSCLC) treated by radiotherapy combined with BAI (bronchial artery infusion) were analyzed retrospectively. In 104 cases (84 males and 20 females), 14 cases of stage I, 10 of stage II, 33 of stage IIIA, 29 of stage IIIB and 18 cases of stage IV were included. Overall cumulative survival rate was 11.4% and 50% survival time was 12 months. On PS (performance status), 50% survival time was 1 year and 3 months for both PS 0 and PS 1, 8 months for PS 2 and 2 year for PS 3 (n = 3), respectively. On stage, 50% survival time was 3 year and 4 months for stage I, 1 year and 2 months for stage II, 12 months for stage IIIA, 11 months for stage IIIB and 8 months for stage IV. There was no significant difference of survival rate between squamous cell carcinoma (n = 41) and adenocarcinoma (n = 43). On anticancer agents used for BAI, CDDP group (n = 68) showed better significant 2-year survival rate than that of MMC and/or ADR group (n = 36). Response rate (CR + PR) was 85% (75/88) by radiotherapy with BAI, and 10 cases of CR were obtained. Among 27 cases of 2-year survivors, 21 cases of responders (CR + PR) were included and 4 cases of them showed CR. On these results, radiotherapy combined with BAI seemed to contribute to improve long-term treatment results of NSCLC by higher response rate with the progress of anticancer agent used for BAI.
回顾性分析104例接受放疗联合支气管动脉灌注（BAI）治疗的非小细胞肺癌（NSCLC）患者的结果。104例患者（84例男性，20例女性）中，包括Ⅰ期14例、Ⅱ期10例、ⅢA期33例、ⅢB期29例和Ⅳ期18例。总累积生存率为11.4%，50%生存时间为12个月。就体能状态（PS）而言，PS 0和PS 1的50%生存时间分别为1年零3个月，PS 2为8个月，PS 3（n = 3）为2年。就分期而言，Ⅰ期的50%生存时间为3年零4个月，Ⅱ期为1年零2个月，ⅢA期为12个月，ⅢB期为11个月，Ⅳ期为8个月。鳞状细胞癌（n = 41）和腺癌（n = 43）之间的生存率无显著差异。就用于BAI的抗癌药物而言，顺铂组（n = 68）的2年生存率显著高于丝裂霉素和/或阿霉素组（n = 36）。放疗联合BAI的缓解率（CR + PR）为85%（75/88），获得10例CR。在27例2年生存者中，包括21例缓解者（CR + PR），其中4例显示CR。基于这些结果，放疗联合BAI似乎通过提高缓解率以及BAI所用抗癌药物的进展，有助于改善NSCLC的长期治疗效果。
